Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Complete Response Letter
Biotech
FDA snubs Fortress' Zydus-partnered Menkes disease candidate
Sentynl and Cyprium were angling the drug candidate to be the first approved treatment for a rare, often fatal pediatric disease.
Zoey Becker
Oct 1, 2025 12:00pm
Capricor responds to cell therapy snub, disputes FDA’s concerns
Sep 9, 2025 11:44am
FDA rejects another ultrarare disease prospect
Sep 8, 2025 10:59am
'Several concerning observations': FDA sheds light on rejections
Sep 5, 2025 10:45am
FDA plans real-time release of drug rejection letters
Sep 4, 2025 1:45pm
FDA flags review of Telix's radiodiagnostic for kidney cancer
Aug 28, 2025 11:20am